However, direct comparisons require caution because: Trial lengths differed Dosing protocols differed Patient populations differed Long-term orforglipron data is still developing A 5% to 10% reduction in body weight can still produce clinically meaningful improvements in blood pressure, insulin sensitivity, mobility, and metabolic health
For GLP-1 therapies, pairing dosing with lived experience is how we move from short-term wins to durable impact, safer titration, and measurable value in the real world
GLP-1 receptor agonists bind to and activate GLP-1 receptors located throughout the body, particularly in pancreatic beta cells, the gastrointestinal tract, and the central nervous system
Tirzepatide, developed by Eli Lilly, is the worlds first dual GLP-1R/GIPR agonist and has shown superior weight loss effects compared to semaglutide
Nutritional deficiencies Individuals using GLP-1s to treat obesity experience significant reductions in appetite and energy intake, with observed caloric reductions of 1639 % [52]
Its so common that it may be present in more than half the worlds population
